For research use only. Not for therapeutic Use.
Ravuconazole（Cat No.:R012780）is a potent, broad-spectrum antifungal agent primarily used in the treatment of fungal infections, including systemic and superficial mycoses. It inhibits the enzyme lanosterol demethylase, a key enzyme in the ergosterol biosynthesis pathway, leading to disrupted fungal cell membrane integrity. Its mechanism of action makes it effective against a wide range of fungi, including Candida species, Aspergillus species, and dermatophytes. With a favorable pharmacokinetic profile, Ravuconazole offers strong efficacy, prolonged activity, and a favorable safety profile, making it an important tool in antifungal therapy.
| Catalog Number | R012780 |
| CAS Number | 182760-06-1 |
| Synonyms | 4-[2-[(1R,2R)-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]benzonitrile; [R-(R*,R*)]-4-[2-[2-(2,4-Difluorophenyl)-2-hydroxy-1?-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]benzonitrile; BMS 207147; ER |
| Molecular Formula | C22H17F2N5OS |
| Purity | ≥95% |
| Storage | -20°C |
| IUPAC Name | 4-[2-[(2R,3R)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile |
| InChI | InChI=1S/C22H17F2N5OS/c1-14(21-28-20(10-31-21)16-4-2-15(9-25)3-5-16)22(30,11-29-13-26-12-27-29)18-7-6-17(23)8-19(18)24/h2-8,10,12-14,30H,11H2,1H3/t14-,22+/m0/s1 |
| InChIKey | OPAHEYNNJWPQPX-RCDICMHDSA-N |
| SMILES | C[C@@H](C1=NC(=CS1)C2=CC=C(C=C2)C#N)[C@](CN3C=NC=N3)(C4=C(C=C(C=C4)F)F)O |
| Reference | </br>1:Potential of Ravuconazole and its Prodrugs as the New OralTherapeutics for Onychomycosis. Yamaguchi H.Med Mycol J. 2016;57(4):E93-E110. PMID: 27904057 Free Article</br>2:Madurella mycetomatis is highly susceptible to ravuconazole. Ahmed SA, Kloezen W, Duncanson F, Zijlstra EE, de Hoog GS, Fahal AH, van de Sande WW.PLoS Negl Trop Dis. 2014 Jun 19;8(6):e2942. doi: 10.1371/journal.pntd.0002942. eCollection 2014 Jun. PMID: 24945848 Free PMC Article</br>3:[In vitro antifungal activity of ravuconazole against isolates of dermatophytes and Candida species from patients with dermatomycoses]. Yamaguchi H, Ikeda F, Iyoda T, Suzuki M, Mikawa T.Med Mycol J. 2014;55(4):J157-63. doi: 10.3314/mmj.55.J157. Japanese. PMID: 25742996 Free Article</br>4:Efficacy of ravuconazole in a murine model of vaginitis by Candida albicans. Elizondo-Zertuche M, Robledo-Leal E, González JG, Ceceñas LA, González GM.Rev Iberoam Micol. 2015 Jan-Mar;32(1):30-3. doi: 10.1016/j.riam.2013.09.006. Epub 2013 Sep 23. PMID: 24071640 </br>5:Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole. Watt K, Manzoni P, Cohen-Wolkowiez M, Rizzollo S, Boano E, Jacqz-Aigrain E, Benjamin DK.Curr Drug Metab. 2013 Feb;14(2):193-202. Review. PMID: 22935068 Free PMC Article</br>6:Hybrids of ravuconazole: synthesis and biological evaluation. Gaikwad ND, Patil SV, Bobade VD.Eur J Med Chem. 2012 Aug;54:295-302. doi: 10.1016/j.ejmech.2012.05.010. Epub 2012 May 15. PMID: 22652223 </br>7:Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Diniz Lde F, Caldas IS, Guedes PM, Crepalde G, de Lana M, Carneiro CM, Talvani A, Urbina JA, Bahia MT.Antimicrob Agents Chemother. 2010 Jul;54(7):2979-86. doi: 10.1128/AAC.01742-09. Epub 2010 Apr 19. PMID: 20404124 Free PMC Article</br>8:Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole. Pasqualotto AC, Thiele KO, Goldani LZ.Curr Opin Investig Drugs. 2010 Feb;11(2):165-74. Review. PMID: 20112166 </br>9:Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp. Demchok JP, Meletiadis J, Roilides E, Walsh TJ.Mycoses. 2010 May;53(3):239-45. doi: 10.1111/j.1439-0507.2009.01700.x. Epub 2009 Mar 7. PMID: 19389068 </br>10:Nonclinical pharmacokinetics of BMS-292655, a water-soluble prodrug of the antifungal ravuconazole. Knipe JO, Mosure KW.Biopharm Drug Dispos. 2008 Jul;29(5):270-9. doi: 10.1002/bdd.612. PMID: 18548464 |
